The aim of this article is to present the current state of knowledge regarding the use of GLP-1 agonists in the treatment of type 2 diabetes, obesity, and other potential clinical indications, including neurodegenerative conditions. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.